Semaglutide is linked to significant weight loss and glucose levels in adults with schizophrenia, overweight/obesity, and prediabetes compared with placebo, new research shows.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/glp-1-promising-option-offset-antipsychotic-weight-gain-2025a1000ob7?src=rss
Author :
Publish date : 2025-09-15 12:01:00
Copyright for syndicated content belongs to the linked Source.
